![Autism And Cbd: What Science Says About Hemp Therapy [FItVIfuYe3z]](https://i0.wp.com/cedclinic.com/wp-content/uploads/2026/09/ced-pexels-13091435.jpg?resize=150%2C150&ssl=1 "Autism And Cbd: What Science Says About Hemp Therapy [FItVIfuYe3z] 2")
#67
Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians need to counsel young cannabis users about potential cardiovascular risks, particularly regarding inflammation and atherosclerosis development, as emerging evidence suggests cannabis use may promote vascular dysfunction beyond previously assumed safety profiles. This research highlights that cannabis affects vascular biology in youth during critical periods of atherosclerotic plaque formation, making it relevant for preventive counseling and risk stratification in primary care and cardiology settings.
This editorial highlights emerging evidence that cannabis use, particularly in young people, may promote atherosclerotic disease through proinflammatory vascular mechanisms rather than being hemodynamically neutral as previously assumed. The authors emphasize that cannabis-induced activation of monocytes and inflammatory pathways can accelerate vascular changes associated with atherosclerosis development, suggesting that the cardiovascular risk profile of cannabis differs substantively from prior characterizations. This finding is particularly concerning given increasing cannabis use among adolescents and young adults during a critical window for cardiovascular risk factor accumulation. Clinicians should recognize that cannabis use may contribute to long-term vascular disease risk through inflammatory mechanisms independent of acute hemodynamic effects, warranting discussion of cardiovascular risks during patient counseling about cannabis use. When counseling young patients considering or actively using cannabis, physicians should incorporate discussion of potential atherosclerotic risk alongside other known cardiovascular effects to support informed decision-making about cannabis consumption.
“This editorial raises important questions about cannabis and vascular inflammation that deserve serious attention, but I’d caution that an editorial itself isn’t the primary evidence—we need to see the underlying research it’s discussing and ideally prospective studies in human populations to understand the clinical magnitude of any risk, particularly in young people where vascular trajectories are still forming.”
💚 This editorial raises important concerns about cannabis use and vascular health in young people, highlighting potential proatherogenic inflammatory pathways involving monocyte activation that challenge the notion that cannabis is cardiovascularly benign. While the mechanistic evidence for cannabis-induced vascular inflammation appears compelling, clinicians should recognize that most of this work remains in early-stage research with limited long-term human outcome data, and that confounders such as smoking method, frequency of use, concurrent tobacco exposure, and underlying cardiovascular risk profiles complicate interpretation of causality. Additionally, the generalizability of findings in youth populations to other age groups or to different cannabis preparations (smoked versus ingested) remains unclear. Nevertheless, given the rising prevalence of cannabis use among adolescents and young adults at a critical window for atherosclerotic development, clinicians should incorporate detailed cannabis use history into cardiovascular risk assessments, counsel patients—especially those with existing risk factors—about
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
